1. Individualizing Treatment Options in Advanced ER-Positive Breast Cancer

3. Introduction Advanced ER-Positive BC

4. Maximizing Time of Tumor Endocrine Sensitivity

5. Case Study 1

6. Biopsy Confirmation of Metastatic Disease

7. First-Line Endocrine Therapy in Advanced Breast Cancer: Choice of ET ± CDK 4/6 Inhibitor

8. FALCON: Anastrozole vs Fulvestrant in Hormone Receptor-Positive Advanced BC

9. FALCON Trial Results

10. FALCON PFS by Patient Subgroups

12. Case Study 2

13. MONALEESA-2: Ribociclib Plus Letrozole vs Letrozole in Hormone Receptor-Positive Advanced BC

14. MONALEESA-2 Results

15. MONALEESA-2 Safety Profile

16. PALOMA-2 Palbociclib Plus Letrozole vs Letrozole Alone

17. PALOMA-2 Results

18. PALOMA-2 AE Summary

19. Case Study 3

20. Case Study 1 (cont)

21. PALOMA-3 Palbociclib Plus Fulvestrant in Premenopausal/Perimenopausal mBC

22. PALOMA-3 Results

23. PALOMA-3 Safety Results

24. BOLERO-2: Everolimus + Exemestane vs Placebo + Exemestane

25. BOLERO-2 Most Common Grade 3/4 AEs

26. Concluding Remarks

27. Abbreviations

28. Abbreviations (cont)